Our mission is to revolutionize the treatment of autoimmune disease by rebalancing the immune system.

This video represents our vision for the future.

Join Us in Shaping the Future of Medicine:

Opportunities for
Investors & Partners

Management Team

Longgui Wang, MD

Chairman, Chief Scientific Officer

Dave Giles, MBA

Chief Executive
Officer

Robert Kirshoff, MS

Chief Clinical Operations Officer

Tim Mikhelashvili, PharmD

Chief Business Development Officer

Autoimmune Disease

The healthy immune system maintains a natural state of balance known as homeostasis

The immune system responds aggressively to neutralize external threats to the human body

Autoimmune disease results when the immune system continues to attack even after the threat has been neutralized

Significant Unmet Need

Leading treatments for autoimmune/inflammatory diseases suppress the immune system

Without immune protection, patients are more susceptible to other serious diseases, including cancers

Discontinuing therapy can also result in rebound of the original threat

Unique Platform

STAT3-SH2 (Y705) Inhibition reduces pro-inflammatory action and increases anti-inflammatory action.

Blocking STAT3-SH2 (Y705) restores balance to the immune system

Once balanced, the immune system can return to its healthy state

Clinically Proven

STA-528, an allosteric inhibitor, specifically blocks STAT3-SH2 (Y705)
activation. Rather than suppressing immune function, it balances the immune system to bolster and maintain the body’s ability to fight disease.

  • STA-528 restores immune homeostasis, possibly
    leading to complete remission – or potentially even
    cure
  • STA-528 suppresses pro-inflammatory Th17/Th1

Path to Market

Focus is on Two Rare Autoimmune/Inflammatory Diseases

  • ALPS

Autoimmune Lymphoproliferative Syndrome

  • MCTD

Mixed Connective Tissue Disease

Pipeline

Leading Innovation in Autoimmune Disease

Get In Touch